TABLE 4.
Adverse effects of patients with COVID-19 treated with and without antimalarial drugs in a tertiary care center in Mexico City.
| N | Overall, N = 626 | HCQ/CLQ, N = 235 | No antimalarial, N = 391 | p-value | |
|---|---|---|---|---|---|
| Hypoglycemia, grade | 494 | 0.57 | |||
| 0 | 473 (96%) | 200 (95%) | 273 (96%) | ||
| 1 | 10 (2.0) | 5 (2.4%) | 5 (1.8%) | ||
| 2 | 4 (0.8%) | 1 (0.5%) | 3 (1.1%) | ||
| 3 | 5 (1.0%) | 2 (1.0%) | 3 (1.1%) | ||
| 4 | 2 (0.4%) | 2 (1.0%) | 0 (0%) | ||
| Leukopenia, grade | 453 | 0.074 | |||
| 0 | 404 (89%) | 171 (86%) | 233 (92%) | ||
| 1 | 38 (8.4%) | 23 (12%) | 15 (5.9%) | ||
| 2 | 11 (2.4%) | 6 (3.0%) | 5 (2.0%) | ||
| 3 | 0 | 0 | 0 | ||
| 4 | 0 | 0 | 0 | ||
| Neutropenia, grade | 451 | 0.41 | |||
| 0 | 422 (94%) | 185 (92%) | 237 (94%) | ||
| 1 | 22 (4.9%) | 10 (5.0%) | 12 (4.8%) | ||
| 2 | 7 (1.6%) | 5 (2.5%) | 2 (0.8%) | ||
| 3 | 0 | 0 | 0 | ||
| 4 | 0 | 0 | 0 | ||
| Thrombocytopenia, grade | 453 | 0.90 | |||
| 0 | 409 (90%) | 179 (90%) | 230 (91%) | ||
| 1 | 41 (9.1%) | 20 (10%) | 21 (8.3%) | ||
| 2 | 1 (0.2%) | 0 (0%) | 1 (0.4%) | ||
| 3 | 2 (0.4%) | 1 (0.5) | 1 (0.4%) | ||
| 4 | 0 (0%) | 0 (0%) | 0 (0%) |
HCQ, hydroxychloroquine; CLQ, chloroquine.